All In MedTech

Device Trial Radar · NCT05387551

CGM and Lifestyle Changes in Patients With Impaired Glucose Tolerance

Effect of Adding Continuous Glucose Monitoring (CGM) to Lifestyle Changes on Insulin Sensitivity in Patients With Impaired Glucose Tolerance

Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Dec 1, 2022

Primary completion

Jun 25, 2026

Study completion Jun 25, 2026

Sponsor

Lead sponsor
Nemours Children's ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 24, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated device
Yes
Who can join
All sexes, from 10 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The incidence of type 2 diabetes (T2D) in children is increasing, paralleling the rising incidence of obesity. Preventing children and adolescents from developing T2D is critical. The health benefits of lifestyle modifications are well documented in this population, but success rates are low. Obesity in children and adolescents increases the risk of not only T2D but other complications as well, such as hypertension, dyslipidemias and more. The investigators hypothesize that having real-time glucose data with the use of a continuous glucose monitor (CGM) in obese patients with impaired glucose tolerance will improve adherence to lifestyle modifications. As a result, a decrease in body mass index (BMI) is expected with subsequent improvement in insulin sensitivity, thus reducing risk of obesity-related complications later in childhood/adolescence and adulthood.

Conditions

  • Impaired Glucose Tolerance
  • Prediabetes

Interventions

  • CGMDevice

    Dexcom G7 sensor, transmitter and supplies will be provided to family for use. Participants will wear G7 and have real-time glucose data throughout the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Insulin Sensitivity Score (ISS)Time frame: Baseline to 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nemours Children's Clinic

    Jacksonville, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.